BiotechTube

400 mg Rifamycin SV dosage + 800 mg Rifamycin SV dosage + 1200 mg Rifamycin SV dosage

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Infectious Diarrhoea

Conditions

Infectious Diarrhoea

Trial Timeline

Feb 1, 2008 → Jul 1, 2008

NCT ID
NCT03447821

About 400 mg Rifamycin SV dosage + 800 mg Rifamycin SV dosage + 1200 mg Rifamycin SV dosage

400 mg Rifamycin SV dosage + 800 mg Rifamycin SV dosage + 1200 mg Rifamycin SV dosage is a phase 2 stage product being developed by Cosmo Pharmaceuticals for Infectious Diarrhoea. The current trial status is completed. This product is registered under clinical trial identifier NCT03447821. Target conditions include Infectious Diarrhoea.

What happened to similar drugs?

4 of 19 similar drugs in Infectious Diarrhoea were approved

Approved (4) Terminated (4) Active (11)
✅AdalimumabAbbVieApproved
✅Daptomycin + Standard of Care (SOC)MerckApproved
✅TigecyclinePfizerApproved
✅Topical Prednisolone Acetate 1%Ocular TherapeutixApproved
🔄LevofloxacinJohnson & JohnsonPhase 3
🔄Tedizolid Phophate + Antibiotic comparator + Aztreonam + MetronidazoleMerckPhase 3
❌Daptomycin + Vancomycin + TeicoplaninNovartisPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03447821Phase 2Completed

Competing Products

20 competing products in Infectious Diarrhoea

See all competitors
ProductCompanyStageHype Score
levofloxacinJohnson & JohnsonPhase 2/3
38
LevofloxacinJohnson & JohnsonPhase 3
40
AdalimumabAbbVieApproved
43
Acalabrutinib + RabeprazoleAstraZenecaPhase 1
29
Cefepime + Ceftolozane + Meropenem + Piperacillin-Tazobactam + TazobactamMerckPhase 2
35
Daptomycin + Standard of Care (SOC)MerckApproved
43
MK-7655 + Imipenem + Cilastatin + Caffeine + Midazolam + OmeprazoleMerckPhase 1
29
TR-701 200 mg + TR-701 300 mg + TR-701 400 mgMerckPhase 2
35
Tedizolid Phophate + Antibiotic comparator + Aztreonam + MetronidazoleMerckPhase 3
40
FTY720 + Oral CorticosteroidNovartisPhase 2
27
Daptomycin + Vancomycin + TeicoplaninNovartisPhase 3
32
PTK 0796 + linezolid + moxifloxacinNovartisPhase 3
32
LFG316 + Conventional TherapyNovartisPhase 2
35
AIN457 + PlaceboNovartisPhase 3
32
AIN457 + AIN457 + AIN457 + PlaceboNovartisPhase 3
32
AIN457 + AIN 457 + AIN457NovartisPhase 2
35
valacyclovirRochePhase 1/2
32
Filgotinib + Placebo to match filgotinib + PrednisoneGilead SciencesPhase 2
27
Tigecycline + vancomycin with aztreonamPfizerPhase 3
40
TigecyclinePfizerApproved
43